

carcinoma patients. This increment may represent the compensatory response of breast carcinoma tissues to estrogen depletion.

**Keywords** Aromatase inhibitors · Breast cancer · Exemestane · Estrogen sulfatase ·  $17\beta$ -hydroxysteroid dehydrogenase · Ki67

## Introduction

Breast cancer is the most common malignancy among women worldwide and the leading cause of cancer-related death in many countries [1, 2]. Approximately 60% of premenopausal and 75% of postmenopausal patients have sex steroid hormone-dependent breast carcinoma [3, 4]. Among these sex steroids, estrogens, especially estradiol or E2, a biologically potent estrogen, play pivotal roles in cell proliferation, development, and invasion of these hormone-dependent breast carcinoma cells [3–5].

Intratumoral estrogen production in breast carcinoma tissues has been advocated by Miller et al. in 1974 [6]. Its clinical significance was in dispute but the presence of local production of estrogens in breast carcinoma tissues has been subsequently reported by others [7, 8]. Aromatase, one of the enzymes involved in estrogen production, was subsequently demonstrated in adipocytes, stromal cells, and carcinoma cells of breast cancer tissues [9–13]. In addition, the other enzymes involved in intratumoral estrogen production (steroid or estrogen sulfatase; STS, estrogen sulfotransferase; EST and  $17\beta$ -hydroxysteroid dehydrogenase type 1;  $17\beta$ -HSD1, etc.) have been also reported to be overexpressed in human breast carcinoma tissues by a number of laboratories [10, 12, 14, 15].

Among these enzymes above, aromatase is the one catalyzing the rate limiting step in the biosynthetic pathway for estrogen [16] and has been considered an important critical target for pharmacological inhibitors which may cause estrogen deprivation for the postmenopausal patients with estrogen receptor (ER) positive breast carcinoma [3, 13, 15]. An introduction of aromatase inhibitors (AIs) in the treatment algorithms of these breast cancer patients has actually been considered one of the major achievements in breast cancer therapy through the last decades [17, 18]. Especially, third-generation AIs suppressed the aromatase activity in the magnitudes of more than 98%, which subsequently resulted in clinical benefits and relatively lower incidences of adverse effects [16, 19]. This therapy has been established as gold standard of endocrine therapy for all stages of ER positive postmenopausal breast cancer patients in numerous countries including Japan.

It is, however, also true that resistance to these endocrine therapies still occurs, which has resulted in serious

clinical problems in the management of these patients above. The mechanisms of this endocrine resistance have been examined by many investigators from the standpoints of either de novo or intrinsic and acquired resistances. Mechanisms of intrinsic or de novo resistance were evident at an initial exposure to endocrine therapy even in some ER abundant tumor cases [4]. The exact mechanisms for this type of resistance have still remained unknown at this juncture. Acquired resistance usually develops during the course of endocrine therapy of the patients who initially respond to the AIs treatment. This mode of resistance has been, in general, explained by a possible adaptation of carcinoma cells to acquire the potential to proliferate despite the inhibition or suppression of aromatization or in situ depletion of estrogens, i.e., de novo acquirement of novel signaling mechanisms to develop a state of estrogen hypersensitivity in breast carcinoma cells, which subsequently circumvent the clinical effects of AIs [4, 16].

Multiple clinical trials have been recently designed in order to examine these resistance mechanisms of AIs [4, 20–24]. A number of putative theories have been proposed to explain the development of this resistance to AIs during the treatment but an adaptation of hormone-dependent breast carcinoma cells to estrogen withdrawal or depletion and develop estrogen hypersensitivity is considered to represent the common biological features [4, 23, 24]. It is also important to note that enzymes other than aromatase are indeed involved in intratumoral estrogen synthesis in human breast carcinoma tissue as described above. However, alterations of these enzymes before and after AIs therapy have not been known at all to the best of our knowledge. Therefore, in this study, we evaluated the changes of the enzymes involved in intratumoral estrogen production including STS,  $17\beta$ -HSD1 and EST in breast carcinoma tissues before and after the neoadjuvant exemestane (EXE) treatment using immunohistochemistry (IHC). We then correlated the findings with the therapeutic responses of individual patients including clinical and pathological responses and alterations of Ki67 before and after the therapy of individual patients. We also correlated the findings with changes of ER, Progesterone receptor (PgR) and human epidermal growth factor receptor type 2 (Her2) in breast carcinoma.

## Materials and methods

### Breast carcinoma cases

116 Japanese postmenopausal patients (55–75 years old), in whom the operable primary breast tumors had been histological diagnosed as primary invasive ductal carcinoma, TNM stage II–IIIa, had been enrolled into the study

of JFMC34-0601[25] of Japanese Foundation for Multidisciplinary Treatment of Cancer between March, 2006 and January, 2008. The menopausal status was defined by natural menopause: at least 1 year since the last menstrual period with the serum level of Follicle-stimulating hormone (FSH) and plasma E2 within the postmenopausal range (FSH  $\geq 30$  IU/L, E2  $< 10$  pmol/l). None had received prior treatment with hormonal agents, chemotherapy or endocrine therapy for breast cancer nor were taking any medications including hormonal preparations at the time of study. None had the past history of breast cancer. All patients provided written informed consents to this study, which had been approved by the local ethics committee or institutional review board.

JFMC34-0601 trial was a multicenter phase II study by Japanese Foundation for Multidisciplinary Treatment of Cancer performed from March 2006 to January 2008. The study was conducted to evaluate the possible efficacy and safety of EXE treatment for 24 weeks administration in Japanese patients with breast carcinoma. 116 Japanese postmenopausal patients had been enrolled into this study and all the patients had been diagnosed as primary operable invasive ductal carcinoma of the breast. Primary clinical endpoints were objective response rates and safety after 24 weeks of the treatment. This trial study demonstrated that 24 weeks EXE treatment was more effective than 16 weeks administration.

According to the protocol of JFMC34-0601 multicenter phase II trial study, all 116 patients initially received EXE as an oral dose of 25 mg daily for 16 weeks and then additional 8 weeks treatment was subsequently given after clinical evaluation done at week 16. Tumor size was serially monitored by calipers and breast ultrasound before treatment, at 16 weeks and at 24 weeks after receiving the neoadjuvant therapy. At week 16, clinical response was assessed and if the patients were evaluated as clinical responders (complete response or partial response or stable disease), 8 weeks of the same treatment was subsequently added until reaching the total treatment period of 24 weeks. However, if the patients were classified as clinical nonresponders (progressive disease), these patients either underwent surgery or received another modes of treatment. All the patients but ten patients (6 patients discontinued the treatment because of adverse effects and 4 patients had been classified as nonresponders) continuously received the therapy until reaching the total period of 24 weeks treatment. At week 24, clinical response was reevaluated and all the patients underwent definitive surgery. The specimens available for examinations in this study were pretreatment core needle biopsies and post treatment surgical specimens which were obtained after the surgery at week 16 or 24. The pre- and posttreatment specimens of 49 patients among these patients were

available for this study of pathological response and the Immunohistochemical evaluation. ER, PgR, and Her2 status was performed by individual institutions by means of standard procedures and retrieved the data for central review and analysis.

#### Clinical response

Clinical response was based on changes in tumor volume taken at 16 weeks and/or 24 weeks after the neoadjuvant therapy. Clinical response was defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumors [26].

#### Pathological response

Tissue sections of the same tumors from pretreatment core needle biopsies and final surgical specimens were obtained and assessed for changes in cellularity and degree of fibrosis in hematoxylin-eosin stained slides. Pathological response was categorized, using the modified criteria described by Miller et al. [27], and assessed as follows: complete when there was no evidence of malignant cell at the original tumor site; partial response when histological decrement in cellularity and/or increment in fibrosis was detected; or no change/nonresponse, by two of the authors above (NC and MC).

#### Immunohistochemistry

One 4- $\mu$ m section of each submitted paraffin blocks of pre- and posttreatment specimens were stained with hematoxylin-eosin to verify an adequate number of invasive breast carcinoma cells and the quality of fixation in order to determine the suitability of further immunohistochemical analyses. Serial tissue sections (4- $\mu$ m) were then prepared from selected blocks and immunohistochemistry was performed to immunolocalize STS, 17 $\beta$ -HSD1, EST and Ki67 as described previously [10, 14, 28]. In brief, IHC staining was performed by streptavidin-biotin amplification method using a Histofine Kit (Nichirei, Tokyo, Japan). The lists of primary antibodies used in this study and concentrations with the antigen retrieval method were summarized in Table 1. Tissue sections of full-term placenta were used as positive controls for STS, 17 $\beta$ -HSD1 and EST.

The immunostained slides were independently evaluated by three of the authors (NC, TS and HS), blinded to clinical outcome of individual patients. STS, 17 $\beta$ -HSD1, and EST immunoreactivity was evaluated using a semi-quantitative method as follows: score 2,  $> 50\%$  positive cells; 1, 1–50% positive cells; and 0, no immunoreactivity,

**Table 1** The list of antibodies employed for immunostaining in this study

Biomarkers	Dilution	Providers
STS (KM1049)	0.37 µg/ml	Kindly provided by, Kyowa medix Co Ltd., Japan
17β-HSD1	1:400	Abnova, Taipei, Taiwan
EST	1:200	MBL, Nagoya, Japan
Ki67	1:100	DAKO, Denmark
ER	Undiluted	Roche diagnostic, Germany
PgR	Undiluted	Roche diagnostic, Germany
Her2	Undiluted	Roche diagnostic, Germany

STS Estrogen sulfatase, 17β-HSD1 17β-hydroxysteroid dehydrogenase type 1, EST estrogen sulfotransferase, Ki 67, Ki 67 protein, ER estrogen receptor, PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2

The pretreatment methods for antigen retrieval were as follows:

17β-HSD1 and EST; microwave in citric buffer, Ki67; autoclave in citric buffer, ER, PgR and Her2; pretreatment by heat in automated machine, STS; no pretreatment was required

as previously described by Suzuki et al. [14]. Evaluation of Ki67 was performed by counting of 1,000 carcinoma cells or more from each cases and the percentage of immunoreactivity was subsequently determined as a labeling index (LI) [28].

In addition, the Ki67 LI was then subclassified, using the criteria described by Miller et al. [27], into three different groups according to the percentage of Ki67 alterations after treatment as follows: Group1; increased group, the Ki67 LI in this group was associated with increment after therapy. Group2; no change group, the Ki67 LI demonstrated unchanged or reduction for less than 40% of the pretreatment level. Group3; decreased group, the Ki67 LI demonstrated the reduction for more than 40% of the pretreatment level. ER and PgR immunoreactivity was scored by assigning proportion and intensity scores, according to Allred's procedure [29]. The membrane staining pattern was estimated in Her2 immunohistochemistry and scored on a scale of 0–3 [30]. ER, PgR, and HER2 were all independently evaluated by two of the authors (TS and HS).

#### Statistical analysis

The Mann–Whitney *U* test was used to compare the pretreatment IHC scores of all biological markers according to the clinical and pathological responses to EXE treatment in individual patients. The Wilcoxon matched-pairs signed-ranks test was employed in order to determine the mean differences between pre- and posttreatment IHC scores of individual biological markers in relation to the clinical and pathological responses status and alterations of Ki67 LI. The correlation among intratumoral enzymes (STS, 17β-HSD1 and EST) were analyzed using Spearman's rank nonparametric correlation test. The statistically significance was considered for the *P* value < 0.05.

#### Results

The breast carcinoma specimens examined before the therapy demonstrated the following features after central review of the specimens; ER+ (100%), PgR+ (85.7%) and Her2+ (77.6%).

#### Clinical and pathological responsiveness

The relevant clinical findings of the patients were summarized in Table 2. All the patients in this study received 16 weeks of EXE treatment but 2 patients were evaluated as PD and the subsequent surgery was advocated at 16 weeks of treatment. Only 47 patients were continuously administrated for EXE treatment until 24 weeks. Clinical response was reevaluated and clinical responders were classified as PR in 27 cases or 55.1% while clinical nonresponders included 19 cases of SD (38.8%) and 3 cases of PD (6.1%) including those previously evaluated as PD (2 patients). Pathological responders and nonresponders corresponded to 22 cases (44.9%) and 27 cases (55.1%),

**Table 2** Clinicopathological features of the patients examined (*n* = 49)

Patients evaluable for IHC	49
Mean age; years (range)	65.6 (56–77)
Tumor stage, <i>n</i> (%)	
T2	49 (100)
Nodal status, <i>n</i> (%)	
N0	39 (79.6)
N1	10 (20.4)
No distant metastasis, M0, <i>n</i> (%)	49 (100)
Clinical stage, <i>n</i> (%)	
Stage IIA	39 (79.6)
Stage IIB	10 (20.4)

**Table 3** Correlation between clinical and pathological responses ( $n = 49$ )

Clinical response	Pathological response		Total
	Response	Nonresponse	
Complete response	0	0	0
Partial response	12	15	27
Stable disease	8	11	19
Progressive disease	2	1	3
Total	22	27	49

respectively. The correlation between clinical and pathological responses was demonstrated in Table 3.

#### Pretreatment evaluation of biological markers according to the responses to EXE

The means of individual biological markers, which were subjected to various responses to EXE treatment, were demonstrated in Table 4. No statistical significance was detected in all the markers examined between clinical and pathological response and nonresponse groups, except for Her2 scoring which was higher in pathological nonresponsive group than that of responsive group.

#### Associations between alterations of biological markers during the therapy and responses to exemestane treatment in individual patients

Alterations of immunohistochemical biomarkers examined in breast tumor tissues before and after EXE neoadjuvant treatment according to clinical and pathological responses

were summarized in Tables 5 and 6. In clinical response group, the significant decrement of Ki67 LI ( $P < 0.0001$ ), ER ( $P = 0.0098$ ) and PgR expression ( $P < 0.0001$ ) was detected. In addition, the statistically significant increment was demonstrated in STS ( $P = 0.0084$ ) and  $17\beta$ -HSD1 ( $P = 0.0015$ ). EST also demonstrated some degrees of increment but this increase did not reach statistical significance ( $P = 0.375$ ). Among clinical nonresponders, STS,  $17\beta$ -HSD1 and EST were all significantly increased ( $P = 0.0078$ ,  $P = 0.0010$  and  $P = 0.0313$ , respectively). In addition, PgR and Ki67 LI demonstrated significant decrement ( $P = 0.0034$  and  $P = 0.0003$ , respectively) but ER and Her2 status did not reveal any significant differences between before and after the therapy (Table 5). In pathological response group, the significant decrement of IHC scores were demonstrated in ER ( $P = 0.0186$ ), PgR ( $P < 0.0001$ ) and Ki67 LI ( $P < 0.0001$ ). Among the enzymes examined, only  $17\beta$ -HSD1 demonstrated statistically significant increment ( $P = 0.0068$ ) (Table 6). In contrast, the intratumoral enzymes in pathological nonresponders, STS,  $17\beta$ -HSD1 and EST were associated with statistically significant increment ( $P = 0.0002$ ,  $P = 0.0001$  and  $P = 0.0156$ , respectively). In addition, the significant decrement was also detected in PgR ( $P = 0.0004$ ) and Ki67 LI ( $P = 0.0003$ ) following the therapy among these nonresponder group.

#### Alterations of intratumoral enzymes and biological markers according to the changes of Ki67 labeling index

Differences of the individual enzyme between pre- and posttreatment were evaluated according to these categories of Ki67 LI described above. Immunoreactivity of STS,

**Table 4** Correlation between immunohistochemical scores of biological markers in breast tumor before treatment and pathological and clinical responses to exemestane

Biological markers	Pathological response			Clinical response		
	R	NR	P value†	R	NR	P value†
STS	1.545 ± 0.5	1.259 ± 0.6	0.1745	1.333 ± 0.6	1.455 ± 0.6	0.5409
$17\beta$ -HSD1	1.409 ± 0.5	1.296 ± 0.5	0.5581	1.333 ± 0.6	1.364 ± 0.5	0.9266
EST	1.727 ± 0.5	1.704 ± 0.5	0.8929	1.815 ± 0.4	1.591 ± 0.5	0.1756
Ki 67	14.045 ± 12.5	11.444 ± 9.5	0.6509	11.815 ± 11.8	13.591 ± 9.7	0.4448
ER	7.273 ± 1.3	7.370 ± 1.6	0.3247	7.704 ± 0.5	6.864 ± 2.0	0.1214
PgR	4.955 ± 2.4	4.889 ± 2.9	0.8561	5.444 ± 2.3	4.273 ± 3.0	0.2082
Her2	0.8636 ± 0.9	1.444 ± 0.8	0.0197*	1.259 ± 0.9	1.091 ± 0.9	0.5294

Data showed by means ± SD

† Mann–Whitney  $U$  test for the difference between R and NR. R response, NR Nonresponse; see text for the details

\*  $P$  value  $< 0.05$  is considered significant

STS estrogen sulfatase,  $17\beta$ -HSD1  $17\beta$ -hydroxysteroid dehydrogenase type 1, EST estrogen sulfotransferase, Ki 67 Ki 67 protein, ER estrogen receptor, PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2

**Table 5** Comparisons of pre- and posttreatment immunohistological scores of biological markers in tumors among groups of different clinical responses to Exemestane

Biological markers	Clinical response		Clinical nonresponse	
	Mean difference [95% CI]	<i>P</i> value†	Mean difference [95% CI]	<i>P</i> value†
STS	-0.4444 [-0.7206, -0.1683]	0.0084*	-0.3636 [-0.5820, -0.1453]	0.0078*
17 $\beta$ -HSD1	-0.4815 [-0.7109, -0.2521]	0.0015*	-0.5 [-0.7269, -0.2731]	0.0010*
EST	-0.7407 [-0.2264, 0.07822]	0.375	-0.2727 [-0.4749, -0.07058]	0.0313*
Ki 67	7.074 [3.453, 10.965]	<0.0001*	6.909 [3.301, 10.517]	0.0003*
ER	0.5556 [0.1401, 0.9710]	0.0098*	0.3636 [-0.1014, 0.8286]	0.1289
PgR	3.333 [2.346, 4.321]	<0.0001*	2.318 [0.8481, 3.788]	0.0034*
Her2	0.1481 [-0.1139, 0.4102]	0.3394	0.04545 [-0.1699, 0.2609]	0.8125

Data showed mean difference for pre IHC value-post IHC value with 95%CI [lower,upper values]; see text for the details

† Wilcoxon match-pairs signed-ranks test for the difference between groups

\* *P* value <0.05 is considered significant

STS estrogen sulfatase, 17 $\beta$ -HSD1 17 $\beta$ -hydroxysteroid dehydrogenase type 1, EST estrogen sulfotransferase, Ki 67 Ki 67 protein, ER estrogen receptor, PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2

**Table 6** Comparisons of pre- and posttreatment immunohistological scoring of biological markers in tumors among groups of different pathological responses to Exemestane

Biological markers	Pathological response		Pathological nonresponse	
	Mean difference [95% CI]	<i>P</i> value†	Mean difference [95% CI]	<i>P</i> value†
STS	-0.2727 [-0.5526, 0.007132]	0.1055	-0.5185 [-0.7479, -0.2891]	0.0002*
17 $\beta$ -HSD1	-0.4545 [-0.7188, -0.903]	0.0068*	-0.5185 [-0.7200, -0.3170]	0.0001*
EST	-0.04545 [-0.2118, 0.1209]	0.75	-0.2593 [-0.4360, -0.08256]	0.0156*
Ki 67	7.636 [4.216, 11.056]	<0.0001*	6.481 [2.758, 10.205]	0.0003*
ER	0.6818 [0.1450, 1.219]	0.0186*	0.2963 [-0.04751, 0.6401]	0.1094
PgR	2.909 [1.859, 3.959]	<0.0001*	2.852 [1.536, 4.167]	0.0004*
Her2	0.04545 [-0.1699, 0.2609]	0.8125	0.1481 [-0.1139, 0.4102]	0.3394

Data showed mean difference for pre-IHC value-post-IHC value with 95% CI [lower,upper values]; see text for the details

† Wilcoxon match-pairs signed-ranks test for the difference between groups

\* *P* value <0.05 is considered significant

STS Estrogen sulfatase, 17 $\beta$ -HSD1 17 $\beta$ -hydroxysteroid dehydrogenase type 1, EST estrogen sulfotransferase, Ki 67 Ki 67 protein, ER estrogen receptor, PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2

17 $\beta$ -HSD1, EST, ER, PgR, and Her2 in pretreatment specimens was not significantly different among these three different groups of Ki67 LI changes (Nonparametric ANOVAs; Data not shown). In group 1 or those whose Ki67 LI increased after the therapy, no statistically significant differences of intratumoral enzymes and biomarkers were detected in the specimens between before and after the treatment. In group 3 or those whose Ki67 LI decreased with more than 40% of the pretreatment level, the significant increment of STS and 17 $\beta$ -HSD1 were demonstrated ( $P = 0.0008$  and  $P = 0.0003$ , respectively). In addition, ER and PgR scorings following the therapy demonstrated significant decrement compared to pretreatment ( $P = 0.0013$  and  $P < 0.0001$ , respectively) in group 3 patients. In group 2 or those whose Ki67 LI unchanged or

decreased with less than 40% of the pretreatment level, only 17 $\beta$ -HSD1 was associated with statistically significant increment ( $P = 0.0313$ ). Moreover, among the enzymes examined and among the other biomarkers examined, only PgR status was significantly decreased following the therapy ( $P = 0.0117$ ) in group 2 patients. EST and Her2 scorings were not different among these three different groups of Ki67 LI alterations (Table 7).

#### Correlation among STS, 17 $\beta$ -HSD1 and EST immunoreactivity before and after EXE treatment

Results were summarized in Table 8. The status of three enzymes examined in this study was significantly correlated among each others in tissue specimens before the

**Table 7** Comparisons of pre- and posttreatment immunohistological scoring of biological markers in tumors according to the degrees of Ki67 changes before and after Exemestane treatment

Biomarkers	Increase		No change		Decrease	
	Mean difference [95% CI]	<i>P</i> value†	Mean difference [95% CI]	<i>P</i> value†	Mean difference [95% CI]	<i>P</i> value†
STS	-0.3333 [-1.417, 0.7507]	0.5000	-0.4000 [-0.7694, -0.3062]	0.1250	-0.4242 [-0.6231, -0.2253]	0.0008*
17β-HSD1	-0.3333 [-0.8753, 0.2087]	0.5000	-0.6000 [-0.9694, -0.2306]	0.0313*	-0.4848 [-0.6855, -0.2842]	0.0003*
EST	-0.5000 [-1.075, 0.07489]	0.0756	-0.1000 [-0.3262, 0.1262]	>0.9999	-0.1212 [-0.2685, -0.02606]	0.1563
ER	0.1667 [-0.8653, 1.199]	>0.9999	-0.1000 [-0.3262, 0.1262]	>0.9999	0.6970 [0.2956, 1.098]	0.0013*
PgR	2.667[-1.298, 6.631]	0.2500	2.800 [0.9286, 4.671]	0.0117*	2.939 [1.905, 3.973]	<0.0001*
Her2	0.000 [-0.6638, 0.6638]	>0.9999	0.2000 [-0.2524, 0.6524]	0.3750	0.09091 [-0.1145, 0.2963]	0.4648

Degrees of Ki67 changes were determined by the changes of labeling index after EXE treatment, i.e., pre value -post value, and subclassified into three groups. Data showed mean difference for pre IHC value-post IHC value with 95%CI [lower,upper values]; see text for the details

† Wilcoxon match-pairs signed-ranks test for the difference between groups

\* *P* value <0.05 is considered significant

STS Estrogen sulfatase, 17β-HSD1 17β-hydroxysteroid dehydrogenase type 1, EST estrogen sulfotransferase, Ki 67 Ki 67 protein, ER estrogen receptor; PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2

**Table 8** Correlation between intratumoral enzymes involved in estrogen production before and after treatment with Exemestane

	STS vs. EST	STS vs. 17β-HSD1	EST vs. 17β-HSD1
Before treatment	<i>r</i> = 0.5402 <i>P</i> < 0.0001*	<i>r</i> = 0.5374 <i>P</i> < 0.0001*	<i>r</i> = 0.4156 <i>P</i> = 0.0030*
After treatment	<i>r</i> = 0.2743 <i>P</i> = 0.0565	<i>r</i> = 0.5983 <i>P</i> < 0.0001*	<i>r</i> = 0.3403 <i>P</i> = 0.0167

Data showed by *r* value and *P* value calculated by Spearman's rank nonparametric correlation test

\* *P* value <0.05 is considered significant correlation


therapy. However, in tumor tissues following the therapy, only the status of STS and 17β-HSD1 was significantly correlated each other.

## Discussion

This is the first study to demonstrate significant alterations of the enzymes other than aromatase involved in intratumoral estrogen production following aromatase inhibitor administration. Several clinical studies have been reported using exemestane as primary endocrine therapy in operable breast cancer patients but results of clinical and pathological responses to exemestane varied among these studies [31–34]. Alterations in tumor histopathological features following aromatase inhibitors administration include the changes in cellularity, degree of fibrosis, histological grading [17, 27], and treatment-related changes of cell proliferation, apoptosis, and hormone receptor expression were also described [31–37].

In tumor specimens following aromatase inhibitors therapy, one of the histological features most frequently or significantly affected was considered the number of mitotic figures or Ki67 positive carcinoma cells, which decreased

in the great majority of cases [17, 36, 37], usually more pronounced than tamoxifen therapy [35]. In IMPACT study [36], Dowsett et al. evaluated the alterations of the number of Ki67 positive carcinoma cells using immunohistochemistry in 10% formalin-fixed and paraffin-embedded tissue sections of both pretreatment and after 2 weeks of neoadjuvant anastrozole treatment. Fifty-two out of 56 patients (93%) were associated with some degree of Ki67 labeling index reduction over the only 2-week period of therapy. Reported results of subsequent IMPACT studies further highlighted the clinical or therapeutic importance of evaluating the changes of Ki67 labeling index of carcinoma cells before and after the treatment [37]. We also demonstrated marked decrement in cell proliferation evaluated by the changes of Ki67 labeling index between before and after the therapy in all clinical and pathological response and nonresponse groups, which is also consistent with results of previously reported studies [17, 33, 36–39]. Therefore, an inhibition of aromatase activity and subsequent in situ decreased tissue estrogen availability were considered to affect the expression of molecules present in the downstream of ER signaling pathways related to cell proliferation regardless of response to treatment [3, 17, 33, 36–39] (Fig. 1).



**Fig. 1** Representative illustrations of immunohistochemistry: (a)  $17\beta$ -HSD1 and (b) STS in the case of invasive ductal carcinoma. Immunoreactivity was detected in the cytoplasm of invasive ductal carcinoma cells in both enzymes. Original magnification  $\times 200$

Changes of the enzymes other than aromatase involved in intratumoral estrogen biosynthesis following aromatase inhibitor therapy have been considered or postulated important in relation to the development of treatment resistance [3] but have remained virtually unknown. To the best of our knowledge, this is the first study demonstrating a significant increment of STS and  $17\beta$ -HSD1 following aromatase inhibitor neoadjuvant therapy of ER positive postmenopausal breast carcinoma patients. We hypothesized that this increment of STS and  $17\beta$ -HSD1 detected in this study may be due to the compensatory response of breast carcinoma tissues to estrogen depletion and may represent an attempt of breast carcinoma to increase intratumoral estrogen concentrations using the estrogen producing or metabolizing pathways other than aromatase. In particular, a significant increment of STS and  $17\beta$ -HSD1 following exemestane treatment was detected in the group associated with decreased Ki67 labeling index in our present study (Table 7). This increment of the enzymes

above was not detected in the group associated with increased Ki67 labeling index, i.e., those associated with an absence of suppression of tumor cell proliferation. However, it awaits further investigations such as the intratumoral regulation of STS and  $17\beta$ -HSD1 under estrogen depletion in order to substantiate this interesting hypothesis.

The simultaneous increase in STS and EST expression detected in our present study may be considered due to intratumoral metabolism and synthesis of estrogens. Both of these enzymes play pivotal roles in intratumoral estrogen production in the hormone-dependent breast carcinoma. STS hydrolyzes estrone sulfate (E1-S) to estrone, while EST sulfonates estrogens to inactive estrogen sulfates [15]. Therefore, an increment of STS levels in breast carcinoma cells may result in increased intratumoral estrogen production, but EST expression may also increase as one of the counterbalance effects or responses to an increment of intracellular estrogen, especially in non-responder groups. However, it awaits further investigations to study the mechanisms of this simultaneous increment of both enzymes.

Among these enzymes examined, in particular,  $17\beta$ -HSD1 was an only intratumoral enzyme whose expression increased regardless of clinical response, pathological response or Ki67 changes of the patients. Suzuki et al. [40] reported that the status of  $17\beta$ -HSD1 immunoreactivity in carcinoma cells was significantly correlated with that of ER and PgR, suggesting estradiol, synthesized by  $17\beta$ -HSD1 in carcinoma cells, act on these cells locally in breast carcinomas. In addition, reductive  $17\beta$ -hydroxysteroid dehydrogenases are the last step in estrogen activation and thus play pivotal roles in biological behavior of ER positive breast carcinoma cells [41]. Sasano et al. [15] also reported that the status of intratumoral aromatase,  $17\beta$ -HSD1, EST and STS in human breast cancer tissues varied markedly among different cases and, especially, no significant correlation was detected between intratumoral aromatase and  $17\beta$ -HSD1. Therefore, an inhibition of  $17\beta$ -HSD1 may be considered to confer clinical or therapeutic benefits upon the patients in whom over-expression of intratumoral  $17\beta$ -HSD1 but not of aromatase was present in breast cancer tissues. The analysis of STS and  $17\beta$ -HSD1 using immunohistochemistry is therefore considered important because these inhibitors may not work unless these enzymes or targets are not present or overexpressed in breast carcinoma cells. Therefore, an analysis of these enzymes as potential surrogate markers of treatment may be required for the successful clinical outcome of treatment when specific inhibitors against these enzymes will be clinically available.

In conclusion, results of this study indicated that an increment of STS and  $17\beta$ -HSD1 may represent at least

one of the mechanisms why hormone-dependent breast carcinoma cells developed resistance to AIs, which also suggest a possible adaptation of carcinoma cells in response to intratumoral estrogen depletion as a result of effective aromatase inhibitor therapy.

**Acknowledgments** We thank the local hospital pathologists who performed tumor sample analysis and other clinicians who were not part of the research team, but took responsibility for patient management. Japanese Foundation for Multidisciplinary Treatment of Cancer was responsible for collating the data in a database. We also thank Kyowa medix co. Ltd Japan for providing a kit of STS antibody.

**Disclosure/conflict of interest** Hironobu Sasano and Yasuhiro Miki received the educational research grant from Pfizer Japan Inc., Tokyo, Japan.

## References

- Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta, GA. [http://www.cancer.org/docroot/STT/STT\\_0.asp](http://www.cancer.org/docroot/STT/STT_0.asp). Accessed 19 Nov 2009
- American Cancer Society (2009) Breast Cancer Facts & Figures 2009–2010. Atlanta, GA: American Cancer Society. [http://www.cancer.org/docroot/STT/STT\\_0.asp](http://www.cancer.org/docroot/STT/STT_0.asp). Accessed 19 Nov 2009
- Pasqualini JR, Chetrite GS (2005) Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. *J Steroid Biochem Mol Biol* 93:221–236
- Chen S, Masri S, Hong YY, Wang X, Phung S, Yuan YC, Wu X (2007) New experimental models for aromatase inhibitor resistance. *J Steroid Biochem Mol Biol* 106:8–15. doi:10.1016/j.jsbmb.2007.05.020
- Sasano H, Nagasaki S, Miki Y, Suzuki T (2009) New developments in intracrinology of human breast cancer estrogen sulfatase and sulfotransferase. *Ann NY Acad Sci* 1155:76–79
- Miller WR, Forrest AP (1974) Oestradiol synthesis by a human breast carcinoma. *Lancet* 2:866–868
- James VH, Reed MJ, Lai LC, Ghilchik MW, Tait GH, Newton CJ, Coldham NG (1990) Regulation of estrogen concentrations in human breast tissues. *Ann NY Acad Sci* 595:227–235
- Larionov AA, Berstein LM, Miller WR (2002) Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. *J Steroid Biochem Mol Biol* 81:57–64
- Miller WR, Hawkins RA, Forrest APM (1982) Significance of aromatase activity in human breast cancer. *Cancer Res* 42: S3365–S3368
- Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S, Ohuchi N, Sasano H (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. *Cancer Res* 67:3945–3954
- Sasano H, Harada N (1998) Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. *Endocr Rev* 19:593–607
- Santen RJ, Leszczynski D, Tilson-Mallet N, Feil PD, Wright C, Manni A, Santner S (1986) Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. *Ann N Y Acad Sci* 464:126–137
- Miller WR, Anderson TJ, Jack WJL (1990) Relationship between tumour aromatase activity, tumour characteristics and response to therapy. *J Steroid Biochem Mol Biol* 37:1055–1059
- Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M, Sasano H (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. *Cancer Res* 63:2762–2770
- Sasano H, Suzuki T, Nakata T, Moriya T (2006) New development in intracrinology of breast carcinoma. *Breast Cancer* 13: 129–136
- Santen RJ (2003) Inhibition of aromatase: insights from recent studies. *Steroids* 68:559–567
- Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM (2005) Aromatase inhibitors: cellular and molecular effects. *J Steroid Biochem Mol Biol* 95:83–89
- Geisler J (2008) Aromatase inhibitors: from bench to bedside and back. *Breast Cancer* 15:17–26
- Geisler J, Lønning PE (2005) Aromatase inhibition: translation into a successful therapeutic approach. *Clin Cancer Res* 11:2809–2821
- Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S (2008) Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. *Cancer Res* 68:4910–4918
- Lønning PE (2009) Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? *Eur J Cancer* 45:527–535
- Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX (2005) Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. *Breast Cancer Res Treat* 94:213–223
- Brodie A, Macedo L, Sabnis G (2009) Aromatase resistance mechanisms in model system in vivo. *J Steroid Biochem Mol Biol*. doi:10.1016/j.jsbmb.2009.09.004
- Flågeng MH, Moi LL H, Dixon JM, Geisler J, Lien EA, Miller WR, Lønning PE, Mellgren G (2009) Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. *Br J Cancer* 101:1253–1260
- Sato N, Masuda N, Saji S, Takei H, Yamamoto Y, Sasano H, Toi M (2009) Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IIIa breast cancer (JFMC34-0601) [abstract 591]. *J Clin Oncol* 27:15S
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* 92:205–216
- Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ (2006) Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. *Br J Cancer* 94:1051–1056
- Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blamey RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. *Br J Cancer* 59:943–947
- Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol* 17:1474–1481
- Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol* 25:118–145
- Takei H, Suemasu K, Inoue K, Saito T, Okubo K, Koh J, Sato K, Tsuda H, Kurosumi M, Tabei T (2008) Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama



- Breast Cancer Clinical Study Group (SBCCSG-03). *Breast Cancer Res Treat* 107:87–94
32. Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R (2008) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCBSG-17). *Breast Cancer Res Treat* 112:203–213
  33. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. *Cancer Sci* 100:2028–2033
  34. Barnadas A, Gil M, González S, Tusquets I, Muñoz M, Arcusa A, Prieto L, Margeli-Vila M, Moreno A (2009) Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. *Br J Cancer* 100:442–449
  35. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ (2003) Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. *Eur J Cancer* 39:462–468
  36. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. *J Clin Oncol* 23:2477–2492
  37. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. *J Natl Cancer Inst* 99:167–170
  38. Anderson H, Bulun S, Ian Smith, Dowsett M (2007) Predictors of response to aromatase inhibitors. *J Steroid Biochem Mol Biol* 106:49–54
  39. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. *J Clin Oncol* 19:3808–3816
  40. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H (2000) 17 $\beta$ -hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. *Br J Cancer* 82:518–523
  41. Aka JA, Mazumdar M, Lin SX (2009) Reductive 17 $\beta$ -hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer. *Mol Cell Endocrinol* 301:183–190

## Total-Circumference Intraoperative Frozen Section Analysis Reduces Margin-Positive Rate in Breast-Conservation Surgery

Kayoko Fukamachi<sup>1</sup>, Takanori Ishida<sup>1</sup>, Shin Usami<sup>1</sup>, Motohiro Takeda<sup>1</sup>, Mika Watanabe<sup>2</sup>, Hironobu Sasano<sup>2</sup> and Noriaki Ohuchi<sup>1,\*</sup>

<sup>1</sup>Department of Surgical Oncology and <sup>2</sup>Department of Pathology, Graduate School of Medicine, Tohoku University, Sendai, Japan

\*For reprints and all correspondence: Noriaki Ohuchi, Department of Surgical Oncology, Tohoku University School of Medicine, Seiryu-chou 1-1, Aoba-ku, Sendai 980-8574, Japan. E-mail: noriakio@m.tains.tohoku.ac.jp

Received September 27, 2009; accepted December 28, 2009

**Objective:** One problem existing in breast-conservation surgery is ipsilateral breast tumour recurrence, and one of its major risk factors is surgical margin positivity. We therefore investigated whether total-circumference surgical margin examination can reduce surgical margin-positive rates.

**Methods:** A total of 122 cases were examined after BCS was performed between March 2004 and March 2006. After partial mastectomy, specimens were taken from the remnant breast side along the total-circumference of the mammary gland (width, approximately 5 mm). Intraoperative frozen section analysis was performed for those specimens. Margin-positive cases were defined as those showing malignancy within  $\leq 5$  mm of the final margin as revealed by final diagnosis.

**Results:** If intraoperative frozen section analysis had not been performed, 33 cases (27%) would have been diagnosed as margin-positive. However, it reduced the number of margin-positive cases to 12 (9.8%), and final margin-positivity rates were thus significantly reduced ( $P < 0.001$ ). As for the accuracy of intraoperative frozen section analysis, sensitivity was 78.6%, specificity was 100%, correct diagnosis rate was 95.1%, positive predictive value was 100% and negative predictive value was 94.0%. False-negatives were caused by the detection of malignancy as revealed in permanent specimens. Margin-positive sites were not limited to the nipple and distal (peripheral) sites, with equivalent margin-positive cases found laterally.

**Conclusions:** Total-circumference surgical margin examination by IFSA for BCS significantly reduced margin-positive rates from 27% to 9.8%.

*Key words:* breast cancer – breast-conservation surgery – frozen section – surgical margin

### INTRODUCTION

In recent years, breast-conservation surgery (BCS) has become a standard operative procedure for breast cancers. One problem that arises with BCS is ipsilateral breast tumour recurrence (IBTR), and one of the major risk factors for such recurrence is surgical margin positivity (1–5). Margin examination by intraoperative frozen section analysis (IFSA) is anticipated to significantly facilitate the correct identification of margin status. As a result, margin examination is currently performed in individual

facilities. However, many issues require further investigation. For instance, methods of specimen submission and evaluation of accurate diagnosis rates are yet to be standardized. Moreover, few detailed reports have examined margin diagnosis within BCS, and no reports have yet clarified the use of IFSA examining the total-circumference (i.e. ‘circumferential’ examination) of the surgical margin.

Ever since we established an environment for performing intraoperative pathological examinations, we have been submitting total-circumference margins shaved from the

mammary gland of the remnant breast for IFSA, and performing margin diagnoses based on these specimens. The present study examined the extent to which circumferential margin examination can reduce surgical margin-positive rates.

## METHODS

The present research was performed in the Department of Breast and Endocrine Surgery at Tohoku University Hospital, in the 2-year period from March 2004 to March 2006, and involved a retrospective study of 122 cases in which BCS had been performed (including three cases of simultaneous dual-breast cancer). During the same periods, 57 patients had received total mastectomy and they were excluded from this study. And cases in which preoperative adjuvant chemotherapy or endocrine therapy had been performed were excluded from analysis, as were cases in which surgical excision biopsy of the main tumour had been performed. Background factors of subjects are shown in Table 1.

Table 1. Characteristics of the 122 patients

Age, years (median)	32–87 (56)
Tumour size, <i>n</i> (%)	
Tis	31 (25.4)
T1 ( $\leq 2$ cm)	74 (60.7)
T2 ( $> 2$ cm, $\leq 5$ cm)	17 (13.9)
Histology, <i>n</i> (%)	
DCIS	31 (25.4)
IDC	81 (66.5)
ILC	2 (1.6)
Mucinous carcinoma	6 (4.9)
Apocrine carcinoma	2 (1.6)
Oestrogen receptor status, <i>n</i> (%)	
Positive	103 (84.4)
Negative	19 (15.6)
Progesterone receptor status, <i>n</i> (%)	
Positive	90 (73.8)
Negative	32 (26.2)
HER2 status, <i>n</i> (%)	
Positive	24 (19.7)
Negative	98 (80.3)
Menopausal status, <i>n</i> (%)	
Premenopausal	45 (36.9)
Postmenopausal	77 (63.1)

DCIS, ductal carcinoma *in situ*; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

## PREOPERATIVE EVALUATION

For the preoperative diagnosis of lesion spread, mammography, ultrasonography, computed tomography (CT) and magnetic resonance imaging were used concomitantly. An overall determination was made for each finding, and the excision range was determined. Particularly with CT, imaging was performed using body surface markers, three-dimensional images were created, and detailed width diagnoses were made (6).

## SURGICAL METHOD

For surgery, wide excision or quadrantectomy was performed after making a skin flap, in principle securing a 2-cm margin from the conjectured lesion. As for lymph node dissection, depending on the case, sampling of Level I to Level III dissection was performed (7).

## ADJUVANT THERAPY

Indication for adjuvant chemotherapy was decided in consideration with histological evidence and according to the report of St Gallen Oncology Conference or Guideline of National Comprehensive Cancer Network. As for adjuvant radiotherapy, most patients underwent except those who refused or contraindicated patients. In this study, 35 patients did not undergo adjuvant radiotherapy.

## MARGIN DIAGNOSIS

After partial mastectomy, specimens were taken from the remnant breast side of the mammary gland with a width of approximately 5 mm, and these specimens were submitted for IFSA (Fig. 1). The outermost surface of the specimen was set as the evaluation surface [Fig. 1 (asterisks)].




Figure 1. Schematic diagram of a total-circumference surgical margin examination. After partial mastectomy, specimens were taken from the remnant breast side of the mammary gland with a width of approximately 5 mm, and these specimens were submitted for IFSA. The outermost surface of the specimen (asterisks) was set as the evaluation surface.

**Table 2.** Results of intraoperative frozen section analysis (IFSA) for the 122 cases and classification of diagnosis pattern

Excised sample margin	IFSA	Final margin diagnosis	No. of cases	Classification of diagnosis <sup>a</sup>
-	-	-	79	
-	+	-	6	A
+	-	-	15	B
+	+	-	10	C
+	+	+	4	D, E
+	-	+	4	F
-	-	+	3	G
-	+	+	1	H
Total			122	

} 33 cases (27%)<sup>b</sup>

} 12 cases (9.8%)<sup>c</sup>

<sup>a</sup>Cases with lesions detected in the excised sample margin, IFSA or final margin diagnosis were divided into types A–H.

<sup>b</sup>Cases in which margin positivity could have been diagnosed without IFSA.

<sup>c</sup>Cases in which margin positivity was diagnosed in the final specimen.

According to the adipose content of the submitted specimen, penetration was made with the proper surfactant, and the sample was frozen in liquid nitrogen. For each specimen, a minimum of two slides were prepared and stained using haematoxylin and eosin. As for margin diagnosis, the basic policy set was that additional excisions would be made of margin-positive portions until the specimen was found to be margin-negative. These frozen specimens were defrosted after evaluation and embedded in paraffin to create permanent specimens. An optical microtome was then used to create sections, and slides were prepared. The diagnosis obtained using these final specimens was considered final.

**PATHOLOGICAL EXAMINATION OF SURGICAL SAMPLES**

For the pathological examination of surgical samples, whole serial slices (width, 5 mm) were created and examined under microscopy. Margin-positive status was defined as the existence of cancer cells (either invasive or non-invasive carcinoma) within 5 mm of the final margin.

Written consent was obtained from all patients for the use of specimens in the present investigation. The  $\chi^2$  test was used for statistical analyses, and values of  $P < 0.05$  were determined significant.

**RESULTS**

The median number of slices submitted for IFSA was seven slices per case (range, 4–12 slices per case). An average of eight slides per case (range, 8–24 slices per case) were prepared and stained using haematoxylin and eosin. It took an average of 53 min per case to perform total-circumference IFSA.

As for margin status according to the need for IFSA, cases were divided into three groups:

Group 1: Could have been determined as margin-negative without IFSA (79 cases).

Group 2: Determined as margin-negative from IFSA (31 cases).

Group 3: Margin-positive despite performance of IFSA (12 cases).

A more detailed investigation of Groups 1–3 was therefore undertaken.

**GROUP IN WHICH MARGIN-NEGATIVE STATUS COULD HAVE BEEN DETERMINED WITHOUT IFSA**

For this group [79 cases (65%), Table 2], preoperative imaging diagnoses were valid, and excisions could thus be made while securing a sufficiently safe margin. Margin diagnoses from excised sample margin, IFSA and final diagnosis were all negative.

**GROUP IN WHICH MARGIN-NEGATIVE STATUS WAS DETERMINED FROM IFSA**

Upon investigation of cases that were finally determined as margin-negative based on IFSA, patterns A, B and C were identified:

- (i) Although margins in the excised sample were negative, skip lesions were identified on slices submitted for IFSA. Since these were considered IFSA-positive, additional excision was performed, and a final diagnosis of margin-negative was obtained. Six cases showed this pattern (Table 2 and Fig. 2A). All these skip lesions were confirmed as cancer occupying in only one or several ducts. There were not multifocal lesions.




Figure 2. Surgical margin-negative cases shown schematically.

- (ii) Although a lesion existed within 5 mm of the excised sample margin, additional cutting of the remnant breast used for IFSA submission secured a sufficient distance between the lesion and the final margin, which was margin-negative. Fifteen cases showed this pattern (Table 2 and Fig. 2B).
- (iii) Since IFSA showed margin-positive status, additional excision was performed and final diagnosis was margin-negative. Ten cases showed this pattern (Table 2 and Fig. 2C).

GROUP IN WHICH MARGIN-POSITIVE STATUS WAS DETERMINED DESPITE IFSA

In 12 cases (10%), final margin status was margin-positive despite the performance of IFSA. Investigation of cases that finally became margin-positive revealed patterns D–H.

- (i) Since these cases were IFSA-positive, additional excision was performed until negative margins were

obtained. However, in the additionally excised slice, permanent specimens revealed lesions. Two cases showed this pattern (Table 2 and Fig. 3A).

- (ii) In two cases, a lesion was confirmed in all of the following: margin of excised sample, IFSA and final margin diagnosis. Of these, a widespread lesion was confirmed in one case even in the additionally excised slice. In that case, total mastectomy was subsequently performed. In the other case, malignancy was also confirmed in the slice submitted for final IFSA, but was limited to just one glandular duct, and the decision was made to achieve control via postoperative radiotherapy. Surgery was therefore considered complete (Table 2 and Fig. 3B).

- (iii) Although these cases showed negative margins in IFSA, cancer was revealed in permanent samples from IFSA slices, resulting in a final diagnosis of margin-positive status. Four cases showed this pattern (Table 2 and Fig. 3C).




Figure 3. Surgical margin-positive cases shown schematically.

- (iv) Although these cases were negative on IFSA, a skip lesion was revealed in the IFSA-slice permanent specimens, and the final diagnosis was thus margin-positive status. Three cases showed this pattern (Table 2 and Fig. 3D).
- (v) Although this case was negative in the excised sample margin, a skip lesion was found in the IFSA slice, and despite additional excision, cancer was revealed in permanent samples from IFSA slices. One case showed this pattern (Table 2 and Fig. 3E).

Among the cases finally determined as margin-positive, with the exception of the two type E cases, all were cases in which the lesion was revealed when sections were made from permanent specimens.

Summarizing the above findings, even if IFSA had not been performed, margin evaluation of the excised sample margin itself would have become the final diagnostic evaluation. That is, in the present investigation of 122 cases, 33 cases (27%; Groups shown in Figs 2B and C, and 3A–C) were diagnosed as margin-positive (Table 2). However, use of IFSA reduced the number of margin-positive cases to 12 (9.8%; Table 2). Final margin-positive rate was thus significantly reduced ( $P < 0.001$ ).

INVESTIGATION OF MARGIN-POSITIVE SITES

With regard to 33 cases that became margin-positive within the first excised sample margin (Table 2), investigation was made of the direction in which margin-positive results were identified. In these cases, tumour cells were identified at the nipple-side margin in 10 cases, the distal-side margin in 11 cases, and lateral-side margins in 23 cases (with some overlap; Fig. 4). Among lateral-side margin-positive cases, 14 cases were diagnosed as positive except for the side nearest to the tumour.

INVESTIGATION OF THE ACCURACY OF INTRAOPERATIVE FSA

For the estimation of correct diagnosis rate, sensitivity, specificity, false-positive rate and false-negative rate, positive




Figure 4. The direction determined as margin-positive in IFSA.

Table 3. Histological characteristics of final margin-positive cases and IFSA-negative cases

	Final margin-positive cases, no. (%)	P-value	IFSA-negative cases, no. (%) <sup>a</sup>	P-value
Histology		0.14		0.67
DCIS	2 (16.7)		25 (26.6)	
IDC	6 (50.0)		63 (67.0)	
ILC	1 (8.3)		1 (1.1)	
Others	3 (25.0)		5 (5.3)	
EIC		0.07		0.36
Positive	8 (80.0)		31 (45.6)	
Negative	2 (20.0)		37 (54.4)	
Lymphovascular invasion		0.41		0.67
Positive	5 (50.0)		30 (44.1)	
Negative	5 (50.0)		38 (55.9)	

DCIS, ductal carcinoma *in situ*; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; EIC, extensive intraductal component. <sup>a</sup>These cases included only cases in which met requirements of final margin-negative and IFSA-negative.

cases were defined as IFSA-positive cases showing positive results on permanent samples from IFSA slices. Likewise, negative cases were defined as IFSA-negative cases showing negative results on permanent samples from IFSA slices. IFSA made in this study showed a sensitivity of 78.6%, a specificity of 100%, and a correct diagnosis rate of 95.1%, and a positive predict value of 100%, and a negative predict value of 94.0%. Cases determined as negative on IFSA, but in which a cancer was afterwards revealed by slicing in the permanent sample, were determined as final margin-positive, and included as ‘false-negative’ cases.

HISTOLOGICAL CHARACTERISTICS

Histological characteristics in the cases with final margin-positive and IFSA-negative are shown in Table 3. The group of IFSA-negative cases included only those which met the requirements of final margin-negative and IFSA-negative. The frequencies of pathological factors compared the group of final margin-positive cases with the other cases. In a similar way, the group of IFSA-negative cases were compared. Patients who had extensive intraductal component (EIC) were more likely to have final margin-positive compared with patients without this characteristic, although there was no significant difference.

DISCUSSION

Many reports have examined relationships between status of surgical margins and IBTR in BCS, and a high rate of IBTR has been seen in cases with positive surgical margins (1–5).

Surgical margins must be taken into consideration when BCS is to be performed, and IFSA is now being performed to ensure negative margins.

In several previous studies, risk factors have been investigated to identify those patients with a high likelihood of having positive margin during BCS (5,8–11). Histological characteristics including ductal carcinoma *in situ* (DCIS), presence of EIC, presence of lymphovascular invasion, multifocality, lobular carcinoma, have all been associated with positive margins. In this study, our result was similar to the previous studies of cases with EIC. It has been shown that the case with EIC has increased the risk of IBTR, particularly severe positive-margin cases. Therefore, these cases must be followed carefully. However, there was not so much of difference about other histological characteristics. The case with multifocal lesions was only two. One was final margin-positive and the other was margin-negative case. There were a few cases of final positive margin in our study. If there were more final margin-positive cases in our study, we might also have been obtaining the data similar to previous studies.

No clear standard currently exists that defines 'margin-positive' within surgical specimens, with a variety of standards existing for different institutions. In the 'Breast Conservation Therapy Guidelines' used in Japan, a determination of margin-positive status is considered reasonable in cases when a cancer is confirmed within 5 mm. Other countries show a broad range of definitions, with some institutions defining 'margin-positive' only when a cancer is exposed at the excision margin, and others diagnosing 'margin-positive', when a cancer has been confirmed within 2 mm or 5 mm (12–18). The accuracy (i.e. correct diagnosis rates) of IFSA thus cannot be determined simply by comparing values from existing reports, and no meaningful discussion can be made regarding the superiority or inferiority of accuracy rates.

In the present investigation, results were obtained under an extremely strict standard compared with those of previously existing reports. As stated earlier, our results regarding the accuracy of margin diagnoses were as follows: sensitivity,

78.6%; specificity, 100%; correct diagnosis rate (diagnostic accuracy rate), 95.1%; positive predictive value, 100%; and negative predictive value, 94.0%. The following rates have been reported previously: sensitivity, 65.0–96.0%; specificity, 84.0–100%; correct diagnosis rate, 83.8–98.0%; positive predictive value, 81.4–97.1%; and negative predictive value, 81.0–100% (12–23). Our values for IFSA were calculated under extremely strict standards of a definition stating 'existence of cancerous cells within 5 mm' and 'cancer identified by slicing with optical microtome from a permanent sample previously determined as negative on IFSA shall be included as a 'false-negative' case'. In previous investigations, no mention has been made of reinvestigation of permanent samples; that is, of slices that had been used for IFSA evaluation after unfreezing. Despite this, accuracy of our IFSA was comparable to results described elsewhere (Table 4). In this study, if margin-positive status was defined as the existence of cancer cells within 2 mm of the final margin, only six margin-positive cases were identified (4.9%). Accuracy rates were as follows: sensitivity, 95.7%; specificity, 100%; correct diagnosis rate, 99.2%; positive predictive value, 100%; and negative predictive value, 99.0%. These values were superior to results described elsewhere.

Furthermore, the majority of cases finally identified as margin-positive were cases in which the lesion first appeared when a reinvestigation was made in the FSA-slice permanent sample. Mammary gland tissue is surrounded by adipose tissue, and thin slices of such adipose tissue are difficult to obtain from frozen samples. As a result, not all gland tissue may show up in the evaluated surface. This is an unavoidable phenomenon characteristic of IFSA, and has been considered as one of the key limitations of IFSA.

Conversely, even in cases where a cancer appears on evaluated surface, frozen specimens are inferior in quality to formalin-fixed permanent samples, and this is thought to have a major impact on the diagnosis. Singletary et al. have stated that since evaluation of structural atypia and nuclear atypia is difficult owing to artefacts from the freezing operation, low-grade DCIS and atypical ductal hyperplasia is

**Table 4.** Comparison of IFSA accuracy of previous reports and our study

Author	No.	Positive <sup>a</sup>	Positive rate (%) <sup>b</sup>	Accuracy (%)	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
Olson et al. (13)	290	<sup>c</sup>	4.1	98.0	73.0	99.5	91.9	98.3
Cabioglu et al. (12)	154	<2 mm	20.0	87.4	77.8	91.7	88.9	86.1
Cendan et al. (14)	97	exposure	22.7	96.0	65.0	100	94.0	100
Weber et al. (15,20)	80	<1 mm	12.5	83.8	80	87.5	81.4	86.5
Ikeda et al. (21)	56	exposure	32.1	91.1	94.4	89.5	97.1	81.0
This study	122	<5 mm	9.8	95.1	78.6	100	100	94.0

<sup>a</sup>Blanks in table represent data not described in that report.

<sup>b</sup>Definition of positive margin.

<sup>c</sup>Margin-positive rate for final margin diagnosis.

extremely difficult to discern from IFSA (24). And papillary lesions were also difficult. Therefore, it was impossible to discern benign and malignant perfectly. IFSA had a limited diagnostic capability. In our institution, several pathologists have diagnosed a sample to avoid misdiagnoses. Fortunately, no misdiagnoses were made in the present investigation; however, this is the point of greatest concern for a pathologist involved in diagnosis, and is thought to be a factor in making IFSA of mammary glands more difficult. To perform accurate IFSA, it is indispensable that the pathologist work together with the surgeon when performing the diagnosis, as a significant portion of this diagnosis can be swayed by the capabilities of the individual pathologist. Inasmuch as there are limitations to any IFSA, margin-positive cases will be impossible to reduce to 0%. Cases diagnosed as margin-positive in the final margin diagnosis have a high possibility of IBTR. Numerous reports have described further excisions or total mastectomy at a later date for such cases (19–21). In the present investigation with 10 cases that finally became margin-positive, only one patient subsequently underwent total mastectomy. In the remaining nine cases, a diagnosis of residual cancer was made for only a limited number of glandular ducts, or, in accordance with the wishes of the patient, further excision was not performed and radiotherapy was used instead. As of the time of writing, although no IBTR has been observed, the mean observation period of 61.4 months has been short, and further observation is obviously required. Strict observation of the clinical course will be especially necessary in these nine cases.

Another novel point in the present investigation was the fact that data were collected over the total-circumference of mammary gland margins. Although other institutions within Japan are performing total-circumference (i.e. circumferential) diagnostic assessments, these are extremely few in number. One reason that can be given for this is the shortage of pathologists in Japan. In IFSA, the diagnosis must be made within a limited time period, and trying to ensure diagnostic accuracy with few pathologists entails limiting the number of slices. Looking at both domestic Japanese and foreign reports, institutions that are performing IFSA over the total-circumference of the mammary gland margin are rare, with most institutions performing partial IFSA. Many institutions submit IFSA for a total of four sites: both sides of the margins nearest to the tumour (i.e. lateral), in addition to the nipple-side margin and the distal-side margin (19,21). As breast carcinoma has a tendency to undergo intraductal extension on the nipple- and distal-sides along the breast duct lobular unit (7,25,26), emphasis is placed on the nipple- and distal-side margins. However, in the present investigation, margin-positive cases were not limited to nipple and distal sides, and equivalent rates were apparent laterally. Ikeda et al. have reported similar results, and noted as a contributing factor that even in cases of quadrantectomy with the margin set at 2 cm, many cases were seen where margins in the nipple and distal directions were  $\geq 2$  cm, meaning that

lateral margins were relatively short (21). Akiyama et al. stated about factor of this result that owing to the breast becoming ptotic, the line of the mammary duct becomes curved, with intertwining breast ducts and lobular unit (27). We simulated the case that we submitted IFSA for a total of four sites, and 19 cases would be diagnosed as final margin-positive. This was more than the actual result. Among lateral-side margin-positive cases, approximately 60% cases were diagnosed as positive except for side nearest to the tumour. This thing was thought to increase margin-positive cases. Therefore, nipple and distal directions and lateral margins all need to be considered, and examination only at the nearest portion of the tumour side is an imperfect procedure.

In the present investigation, even supposing that IFSA had not been performed, evaluation of the specimen margins themselves would have constituted the final margin evaluation. In other words, among the 122 cases, 33 (27%) (Groups shown in Figs 2B and C, and 3A–C) were diagnosed as margin-positive (Table 2). However, because of the performance of IFSA, the number of margin-positive cases could be reduced to 12 (9.8%; Table 2). Final margin-positive rates were thus significantly reduced ( $P < 0.001$ ). Among cases successfully diagnosed as margin-negative because of the performance of IFSA, with regard to the six cases of Group A, no continuity was seen between lesions in these specimens and those in slices submitted for IFSA. Skip lesions existed coincidentally among the portions submitted as margins, and the possibility of lesions existing even further outside the final margins cannot be denied. Thus, in the strictest sense, evaluating whether margin-positive status was successfully determined by IFSA is difficult.

Whether ideal circumferential margin examinations would always be possible is a difficult issue, and the necessity is controversial. There are problems such as securement of pathologists, labour of making many histological preparation and restriction of operating time. Therefore, it is unreal to perform total-circumference margin examination in all patients. Nevertheless, performance of total-circumference surgical margin examination can save cases. Therefore, even more accurate determination of cases warranting total-circumference surgical margin examination is needed in the future.

## CONCLUSION

Currently, the number of facilities performing total-circumference surgical margin examination by IFSA is limited, and performing this examination for every case of BCS is unrealistic. In the present study, because of the use of this examination on the basis of an extremely strict standard, we reduced surgical margin-positive status from 27% to 9.8%. Thus, with the performance of this examination that is appropriate for each specific case, it should be possible to save even more cases.



**Conflict of interest statement**

None declared.

**References**

- Leborgne F, Leborgne JH, Ortega B, Doldan R, Zubizarreta E. Breast conservation treatment of early stage breast cancer: patterns of failure. *Int J Radiat Oncol Biol Phys* 1995;31:765–75.
- Horiguchi J, Iino Y, Takei H, Maemura M, Yokoe T, Niibe H, et al. Surgical margin and breast recurrence after breast-conserving therapy. *Oncol Rep* 1999;6:135–8.
- Wazer DE, Jabro G, Ruthazer R, Schmid C, Safaii H, Schmidt-Ullrich RK. Extent of margin positivity as a predictor for local recurrence after breast conserving irradiation. *Radiat Oncol Invest* 1999;7:111–7.
- Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. *N Engl J Med* 1996;334:1356–61.
- Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. *J Clin Oncol* 2000;18:1668–75.
- Harada-Shoji N, Yamada T, Ishida T, Amari M, Suzuki A, Moriya T, et al. Usefulness of lesion image mapping with multidetector-row helical computed tomography using a dedicated skin marker in breast-conserving surgery. *Eur Radiol* 2009;19:868–74.
- Ohuchi N. Breast-conserving surgery for invasive cancer: a principle based on segmental anatomy. *Tohoku J Exp Med* 1999;188:103–18.
- Obedian E, Haffty BG. Negative margin status improves local control in conservatively managed breast cancer patients. *Cancer J Sci Am* 2000;6:28–33.
- Tartter PI, Kaplan J, Bleiweiss I, Gajdos C, Kong A, Ahmed S, et al. Lumpectomy margins, reexcision, and local recurrence of breast cancer. *Am J Surg* 2000;179:81–5.
- Luu HH, Otis CN, Reed WP, Jr, Garb JL, Frank JL. The unsatisfactory margin in breast cancer surgery. *Am J Surg* 1999;178:362–6.
- Chagpar AB, Martin RC, II, Hagendoorn LJ, Chao C, McMasters KM. Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique. *Am J Surg* 2004;188:399–402.
- Cabioglu N, Hunt KK, Sahin AA, Kucrer HM, Babiera GV, Singletary SE, et al. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. *Ann Surg Oncol* 2007;14:1458–71.
- Olson TP, Harter J, Munoz A, Mahvi DM, Breslin T. Frozen section analysis for intraoperative margin assessment during breast-conserving surgery results in low rates of re-excision and local recurrence. *Ann Surg Oncol* 2007;14:2953–60.
- Cendan JC, Coco D, Copeland EM, III. Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins. *J Am Coll Surg* 2005;201:194–8.
- Weber WP, Engelberger S, Viehl CT, Zanetti-Dallenbach R, Kuster S, Dirnhofner S, et al. Accuracy of frozen section analysis versus specimen radiography during breast-conserving surgery for nonpalpable lesions. *World J Surg* 2008;32:2599–606.
- Huston TL, Pigalarga R, Osborne MP, Tousimis E. The influence of additional surgical margins on the total specimen volume excised and the reoperative rate after breast-conserving surgery. *Am J Surg* 2006;192:509–12.
- Schmidt-Ullrich R, Wazer DE, Tercilla O, Safaii H, Marchant DJ, Smith TJ, et al. Tumor margin assessment as a guide to optimal conservation surgery and irradiation in early stage breast carcinoma. *Int J Radiat Oncol Biol Phys* 1989;17:733–8.
- Assersohn L, Powles TJ, Ashley S, Nash AG, Neal AJ, Sacks N, et al. Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. *Ann Oncol* 1999;10:1451–5.
- Noguchi M, Minami M, Earashi M, Taniya T, Miyazaki I, Mizukami Y, et al. Intraoperative histologic assessment of surgical margins and lymph node metastasis in breast-conserving surgery. *J Surg Oncol* 1995;60:185–90.
- Weber S, Storm FK, Stitt J, Mahvi DM. The role of frozen section analysis of margins during breast conservation surgery. *Cancer J Sci Am* 1997;3:273–7.
- Ikeda T, Enomoto K, Wada K, Takeshima K, Yoneyama K, Furukawa J, et al. Frozen-section-guided breast-conserving surgery: implications of diagnosis by frozen section as a guide to determining the extent of resection. *Surg Today* 1997;27:207–12.
- Bianchi S, Palli D, Ciatto S, Galli M, Giorgi D, Vezzosi V, et al. Accuracy and reliability of frozen section diagnosis in a series of 672 nonpalpable breast lesions. *Am J Clin Pathol* 1995;103:199–205.
- Ferreiro JA, Myers JL, Bostwick DG. Accuracy of frozen section diagnosis in surgical pathology: review of a 1-year experience with 24,880 cases at Mayo Clinic Rochester. *Mayo Clin Proc* 1995;70:1137–41.
- Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. *Am J Surg* 2002;184:383–93.
- Ishida T, Furuta A, Moriya T, Ohuchi N. Pathological assessment of intraductal spread of carcinoma in relation to surgical margin state in breast-conserving surgery. *Jpn J Clin Oncol* 2003;33:161–6.
- Ohuchi N, Furuta A, Mori S. Management of ductal carcinoma *in situ* with nipple discharge. Intraductal spreading of carcinoma is an unfavorable pathologic factor for breast-conserving surgery. *Cancer* 1994;74:1294–302.
- Akiyama F, Takahashi K, Kasumi F, Sakamoto G. Histopathological diagnosis of surgical margin of breast conservative surgery. *Jpn J Breast Cancer* 2003;18:404–11.

## American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett, D. Craig Allred, Karen L. Hagerty, Sunil Badve, Patrick L. Fitzgibbons, Glenn Francis, Neil S. Goldstein, Malcolm Hayes, David G. Hicks, Susan Lester, Richard Love, Pamela B. Mangu, Lisa McShane, Keith Miller, C. Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony Rhodes, Hironobu Sasano, Jared N. Schwartz, Fred C.G. Sweep, Sheila Taube, Emina Emilia Torlakovic, Paul Valenstein, Giuseppe Viale, Daniel Visscher, Thomas Wheeler, R. Bruce Williams, James L. Wittliff, and Antonio C. Wolff

### A B S T R A C T

#### Purpose

To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers.

#### Methods

The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance.

#### Results

Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria.

#### Recommendations

The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.

This guideline was developed through a collaboration between American Society of Clinical Oncology and College of American Pathologists and has been published jointly by invitation and consent in both the *Journal of Clinical Oncology* and the *Archives of Pathology & Laboratory Medicine*. Copyright © 2010 American Society of Clinical Oncology and College of American Pathologists. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by American Society of Clinical Oncology or College of American Pathologists.

### INTRODUCTION

In 2008, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) decided to pursue an investigation of whether a guideline for estrogen receptor (ER) and progesterone receptor (PgR) testing would be necessary and beneficial for patients with breast cancer.

The two organizations had published a joint guideline on human epidermal growth factor receptor 2 (HER2) testing in 2007.<sup>1,2</sup> A new Expert Panel was convened to address this issue in 2008, and a document reflecting their expert and evidence-based opinions was developed and approved by both organizations. This version of that document is abbreviated from the original approved document, which

From Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT; Washington University School of Medicine, St Louis, MO; American Society of Clinical Oncology, Alexandria, VA; University of Michigan Comprehensive Cancer Center, University of Michigan Health System; St Joseph Mercy Hospital; Gemini Group, Ann Arbor; Advanced Diagnostics Laboratory, Redford, MI; Presbyterian Hospital, Charlotte, NC; Indiana University, Bloomington, IN; St Jude Medical Center, Fullerton, CA; University of Rochester, Rochester, NY; Brigham and Women's Hospital, Boston, MA; National Cancer Institute, Bethesda; ST Consulting, Glen Echo; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Ohio State University, Columbus, OH; Baylor College of Medicine, Houston, TX; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; The Delta Pathology Group, Shreveport, LA; University of Louisville, Louisville, KY; Royal Marsden Hospital, London; United Kingdom National External Quality Assessment Service, Sheffield; University of West of England, Bristol, United Kingdom; Princess Alexandra Hospital, Brisbane, Queensland, Australia; University of British Columbia, Vancouver, British Columbia; Royal University Hospital, Saskatoon, Saskatchewan, Canada; Tohoku University School of Medicine, Sendai, Japan; Radboud University, Nijmegen, the Netherlands; and European Institute of Oncology and University of Milan, Milan, Italy.

Submitted August 14, 2009; accepted February 23, 2010; published online ahead of print at www.jco.org on April 19, 2010.

Steering Committee members: M.E.H.H., D.F.H., M.D., D.C.A., and A.C.W.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: ASCO, Cancer Policy and Clinical Affairs, 2318 Mill Rd, Suite 800, Alexandria, VA 22314; e-mail: guidelines@asco.org.

© 2010 by American Society of Clinical Oncology and College of American Pathologists

0732-183X/10/2816-2784/\$20.00

DOI: 10.1200/JCO.2009.25.6529

is available online and includes introductory sections dealing with ER physiology and measurement, history of ER testing, and discussion of the current issues related to ER and PgR testing for patients with breast cancer.

### GUIDELINE QUESTIONS

The overall purpose of this guideline is to improve the accuracy of hormone receptor testing and the utility of ER and PgR as prognostic and predictive markers for assessing in situ and invasive breast carcinomas. Therefore, this guideline addresses two principal questions regarding ER and PgR testing. Findings are listed in Table 1.

1. What is the optimal testing algorithm for determining ER and PgR status?
  - 1.1. What are the clinically validated methods that can be used in this assessment?
2. What strategies can ensure optimal performance, interpretation, and reporting of established assays?
  - 2.1. What are the preanalytic, analytic, and postanalytic variables that must be controlled to ensure that assay results reflect tumor ER and PgR status?
  - 2.2. What is the optimal internal quality management regimen to ensure ongoing accuracy of ER and PgR testing?
  - 2.3. What is the regulatory framework that permits application of external controls such as proficiency testing and on-site inspection?
  - 2.4. How can internal and external control efforts be implemented and their effects measured?

The Panel also reviewed a few special questions.

1. Should immunohistochemistry (IHC) of ER/PgR be performed in ductal carcinoma in situ (DCIS) or recurrent breast cancer specimens?
2. Does PgR expression in breast cancer correlate with or influence the choice of endocrine therapy?

### PRACTICE GUIDELINES

ASCO/CAP's practice guidelines reflect expert consensus based on the best available evidence. They are intended to assist physicians and patients in clinical decision making and to identify questions and settings for further research. With the rapid flow of scientific information in oncology, new evidence may emerge between the time an updated guideline was submitted for publication and when it is read or appears in print. Guidelines are not continually updated and may not reflect the most recent evidence. Guidelines address only the topics specifically identified in the guideline and are not applicable to interventions, diseases, or stages of diseases not specifically identified. Furthermore, guidelines cannot account for individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine the best course of treatment for the patient. Accordingly, adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made by the physician in light of each patient's individual circum-

stances and preferences. ASCO/CAP guidelines describe the use of procedures and therapies in clinical practice and cannot be assumed to apply to the use of interventions in the context of clinical trials. ASCO and CAP assume no responsibility for any injury or damage to persons or property arising out of or related to any use of ASCO/CAP's guidelines or for any errors or omissions.

### METHODS

#### Panel Composition

The ASCO Clinical Practice Guidelines Committee (CPGC) and the CAP Council on Scientific Affairs (CSA) jointly convened an Expert Panel (hereafter referred to as the Panel) consisting of experts in clinical medicine and research relevant to hormone receptor testing, including medical oncology, pathology, epidemiology, statistics, and health services research. Academic and community practitioners, a patient representative, and experts from the US National Cancer Institute (NCI) and international organizations were also part of the Panel. Representatives from the US Food and Drug Administration (FDA) and the US Centers for Medicare and Medicaid Services served as ex-officio members. The opinions of Panel members associated with official government agencies like the US National Cancer Institute represent their individual views and not necessarily those of the agency with which they are affiliated. The Panel members are listed in Appendix Table A1 (online only). Representatives of commercial laboratories and assay manufacturers (Appendix Table A2, online only) were invited as guests to attend the open portion of the 2-day meeting held at ASCO headquarters in Alexandria, VA, in December 2008. The planning, deliberations, and manuscript drafting were led by a six-member steering committee composed of two ASCO representatives (Drs Hayes and Wolff), two CAP representatives (Drs Hammond and Schwartz), and two additional experts in testing and evaluation of ER (Drs Allred and Dowsett).

#### Literature Review and Analysis

*ASCO/Cancer Care Ontario (CCO) Systematic Review.* ASCO and CAP commissioned a systematic review of the literature on hormone receptor testing published since 1990. That review conducted by ASCO and CCO is being published separately (manuscript in preparation) and served as the primary source of the evidence for this guideline. Articles were selected for inclusion in the systematic review if they met the following prospective criteria. Studies comparing IHC in paraffin-embedded female breast cancer sections with another assay and comparative studies whose objectives were to improve or validate the quality of IHC studies that linked test performance to clinical outcome were specifically sought. Systematic reviews, consensus statements, and practice guidelines from 1990 onward were included if they addressed hormone receptor testing in female breast cancer using IHC in paraffin-embedded sections or gene expression signatures for ER and PgR. A cutoff date of 1990 was chosen because this was the time that IHC began to come into common use. Additional details of the literature search strategy are provided in the Systematic Review (manuscript in preparation).

*ASCO/CAP Expert Panel literature review and analysis.* The Panel reviewed all data from the systematic review, as well as additional studies obtained from personal files.

**Table 1.** Summary of Guideline Recommendations for ER and PgR Testing by IHC in Breast Cancer Patients

	Recommendation	Comments
Optimal algorithm for ER/PgR testing	<p>Positive for ER or PgR if finding of <math>\geq 1\%</math> of tumor cell nuclei are immunoreactive.</p> <p>Negative for ER or PgR if finding of <math>&lt; 1\%</math> of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls are seen).</p> <p>Uninterpretable for ER or PgR if finding that no tumor nuclei are immunoreactive and that internal epithelial elements present in the sample or separately submitted from the same sample lack any nuclear staining.</p>	<p>These definitions depend on laboratory documentation of the following:</p> <ol style="list-style-type: none"> <li>1. Proof of initial validation in which positive ER or PgR categories are 90% concordant and negative ER or PgR categories are 95% concordant with a clinically validated ER or PgR assay.<sup>3</sup></li> <li>2. Ongoing internal QA procedures, including use of external controls of variable ER and PgR activity with each run of assay, regular assay reassessment, and competency assessment of technicians and pathologists.</li> <li>3. Participation in external proficiency testing according to the proficiency testing program guidelines.</li> <li>4. Biennial accreditation by valid accrediting agency.</li> </ol>
Optimal testing conditions	<p>Large, preferably multiple core biopsies of tumor are preferred for testing if they are representative of the tumor (grade and type) at resection.</p> <p>Interpretation follows guideline recommendation.</p>	<p>Specimen should be rejected and testing repeated on a separate sample if any of the following conditions exist:</p> <ol style="list-style-type: none"> <li>1. External controls are not as expected (scores recorded daily show variation).</li> <li>2. Artifacts involve most of sample.</li> </ol> <p>Specimen may also be rejected and testing repeated on another sample if:</p> <ol style="list-style-type: none"> <li>1. Slide has no staining of included normal epithelial elements and/or normal positive control on same slide.</li> <li>2. Specimen has been decalcified using strong acids.</li> <li>3. Specimen shows an ER-negative/PgR-positive phenotype (to rule out a false-negative ER assay or a false-positive PgR assay).</li> <li>4. Sample has prolonged cold ischemia time or fixation duration <math>&lt; 6</math> hours or <math>&gt; 72</math> hours and is negative on testing in the absence of internal control elements.</li> </ol> <p>Positive ER or PgR requires that <math>\geq 1\%</math> of tumor cells are immunoreactive. Both average intensity and extent of staining are reported. Image analysis is a desirable method of quantifying percentage of tumor cells that are immunoreactive. H score, Allred score, or Quick score may be provided. Negative ER or PgR requires <math>&lt; 1\%</math> of tumor cells with ER or PgR staining. Interpreters have method to maintain consistency and competency documented regularly.</p>
Optimal tissue handling requirements	<p>Accession slip and report must include guideline-detailed elements.</p> <p>Time from tissue acquisition to fixation should be as short as possible.</p> <p>Samples for ER and PgR testing are fixed in 10% NBF for 6 to 72 hours. Samples should be sliced at 5-mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of NBF to allow adequate tissue penetration. If tumor comes from remote location, it should be bisected through the tumor on removal and sent to the laboratory immersed in a sufficient volume of NBF. Cold ischemia time, fixative type, and time the sample was placed in NBF must be recorded.</p> <p>As in the ASCO/CAP HER2 guideline, storage of slides for more than 6 weeks before analysis is not recommended.</p> <p>Time tissue is removed from patient, time tissue is placed in fixative, duration of fixation, and fixative type must be recorded and noted on accession slip or in report.</p>	
Optimal internal validation procedure	<p>Validation of any test must be done before test is offered. See separate article on testing validation (Fitzgibbons et al<sup>3</sup>).</p> <p>Validation must be done using a clinically validated ER or PgR test method. Revalidation should be done whenever there is a significant change to the test system, such as a change in the primary antibody clone or introduction of new antigen retrieval or detection systems.</p>	
Optimal internal QA procedures	<p>Initial test validation. See separate article on testing validation (Fitzgibbons et al<sup>3</sup>).</p> <p>Ongoing quality control and equipment maintenance.</p> <p>Initial and ongoing laboratory personnel training and competency assessment.</p> <p>Use of standardized operating procedures including routine use of external control materials with each batch of testing and routine evaluation of internal normal epithelial elements or the inclusion of normal breast sections on each tested slide, wherever possible.</p> <p>Regular, ongoing assay reassessment should be done at least semiannually (as described in Fitzgibbons et al<sup>3</sup>). Revalidation is needed whenever there is a significant change to the test system.</p> <p>Ongoing competency assessment and education of pathologists.</p>	

(continued on following page)